Corcept Therapeutics Reports Positive Phase 3 Results for Relacorilant in Platinum-Resistant Ovarian Cancer
Reuters
Oct 19, 2025
Corcept <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 3 Results for Relacorilant in Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated has announced new data from its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The results, presented at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting, demonstrated a progression-free survival benefit, particularly in patients whose disease progressed while on or after taking a PARP inhibitor. Additionally, Corcept reported the expansion of its Phase 2 BELLA trial to three study arms, which will examine the efficacy and safety of relacorilant plus nab-paclitaxel and bevacizumab in platinum-resistant and platinum-sensitive ovarian cancer, as well as relacorilant plus nab-paclitaxel in endometrial cancer. Initial results from the BELLA trial are expected in late 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251019109551) on October 19, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.